Chemotherapie bij hersentumoren

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 13, 1996, Pages 702-706

  Van Den Bent, M J ^a,b   Schellens, J H M ^a,b   Sillevis Smitt, P A E ^a,b   Vecht, Ch J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Afd Neuro oncologie ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CORTICOSTEROID; DACARBAZINE; DEXAMETHASONE; LOMUSTINE; MITOLACTOL; PROCARBAZINE; SEMUSTINE;

BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN EDEMA; BRAIN METASTASIS; DRUG PENETRATION; DRUG SENSITIVITY; GLIOMA; HUMAN; NAUSEA; PROGNOSIS; SHORT SURVEY;

ADRENAL CORTEX HORMONES; ADULT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS; LYMPHOMA; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; TREATMENT OUTCOME;

EID: 5644229889     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Steward DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994;20:121-39.
2. Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG. Dexamethasone effects on [125l]albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 1987;7:687-701.
3. Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994;44:1721-7.
4. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-9.
5. Macdonald DR, Cascino TL, Schold jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
6. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993;29A:940-2.
7. Cairncross JG, Macdonald DR, Pexman JHW, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724-6.
8. Coia LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992;13:229-38.
9. Hoskin PJ, Crow J, Ford HT. The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 1990;19:111-5.
10. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832-9.
11. Boogerd W, Dalesio O, Bais EM, Sande JJ van der. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-80.
12. Sorensen PS, Kristjansen PEG, Wagner A, Hansen HH. Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. Acta Neurol Scand 1994;89:372-7.
13. Kristensen CA, Kristjansen PEG, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer a review. J Clin Oncol 1992;10:1498-502.
14. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989,7:916-22.
15. Groen HJM, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 1993;29A:1696-9.
16. Postmus PE, Smit EF, Berendsen HH, Sleijfer DT, Haaxma-Reiche H. Treatment of brain metastases of small cell lung cancer with teniposide. Semin Oncol 1992;19 (2 Suppl 6):89-94.
17. Postmus PE, Smit EF, Haaxma-Reiche H, Zandwijk N van, Ardizzoni A, Quoix E, et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study. J Clin Oncol 1995;13.660-5.
18. Cooper KG, Kitchener HC, Parkin DE. Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin. Gynecol Oncol 1994;55:318-23.
19. Rustin GJS, Newlands ES, Bagshawe KD, Begent RHJ, Crawford SM. Successful management of metastatic and primary germ cell tumors in the brain. Cancer 1986;57:2108-13
20. Rustin GJS, Newlands ES, Begent RHJ, Dent J, Baghawe KD. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7:900-3.
21. Vecht ChJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993:33:583-90.
22. Slooff JL. Neuropathology. In. Twijnstra A, Keyser A, Ongerboer de Visser BW, editors. Neuro-oncology. Primary tumors and neurological complications of cancer. Amsterdam: Elsevier, 1993:101-16.
23. Walker MD, Green SB, Byar DP, Alexander jr E, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
24. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52: 997-1007.
25. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 1994;44:1479-83.
26. Trojanowski T, Peszynski J, Turowski K, Kaminski S, Goscinski I, Reinfus M, et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. J Neurooncol 1988;6:285-91.
27. Fine HA, Dear KBG, Loeffler JS, Black PMCL, Canells GP. Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant ghomas in adults. Cancer 1993;71:2585-97.
28. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-4.
29. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
30. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992;10:766-71.
31. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992;10:1074-7.
32. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, et al. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994:12.414-20.
33. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994;19:69-74.
34. Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989;64:2420-3.
35. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-88.
36. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21.
37. Soffietti R, Chiòm A, Mocellini C, Rudà R, Vigliani M, Schiffer D Response of oligodendroglial tumors to PCV chemotherapy [abstract]. Neurology 1994;44 (Suppl 2):A309.
38. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989;63:939-47.
39. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
40. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-95.
41. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
42. Boiardi A, Silvani A, Valentini S, Salmaggi A, Allegranza A, Broggi G. Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. J Neurol 1993;241:96-100.